STRM.BIO is usefully understood as a pre-clinical company leveraging extracellular vesicles (EVs) to deliver gene therapy in a better way: simpler, safer, practical. With a particuar emphasis on opening the door to the future of medicine for patients living with rare diseases worldwide, STRM.BIO (storm bio) is a pre-clinical biotech firm tackling fulfillment of the promise of gene therapy by leveraging extracellular vesicles (EVs) to deliver treatment directly to the patient (in vivo). Underpinning what the firmis about, the principals note that - unlike viruses, - EVs are natural carriers of nucleic acids and proteins with innate targeting capabilities, amenability to large scale/commercial manufacture, and low immunogenicity. These factors make them excellent cell messengers for gene therapies. STRM.Bio's proprietary EV platform is structured around establishing a whole new class of therapeutics, yielding new therapies and making existing ones more effective.
